Dendritic cell-based immunotherapy (DCVAC/OvCa) withchemotherapy in patients with platinum-sensitive, relapsed,epithelial ovarian carcinoma: Survival analysis of a phase II,open-label, randomized, multicenter trial (study SOV02)

Cibula, D., Rob, L., Mallmann, P., Knapp, P., Bartůňková, J., Spíšek, R., Hassan, H. I., Pecen, L., Klat, J., Chovanec, J. Dendritic cell-based immunotherapy (DCVAC/OvCa) withchemotherapy in patients with platinum-sensitive, relapsed,epithelial ovarian carcinoma: Survival analysis of a phase II,open-label, randomized, multicenter trial (study SOV02). Gynecologic Oncology. 2019, 154(suppl. 1), 18-18. ISSN 0090-8258. E-ISSN 1095-6859. Available: doi: 10.1016/j.ygyno.2019.04.046